So the most important advance in Lewy body dementia is the rapid progress toward reliable biomarkers, especially those targeting alpha-synuclein, which is the core disease protein of Lewy body dementia, as well as Parkinson’s and what’s becoming clear, a co-pathology in Alzheimer’s. At ADDF, we’ve supported the development of a biomarker test from Amprion. And this test detects misfolded alpha-synuclein from just a few drops of cerebrospinal fluid, or CSF...
So the most important advance in Lewy body dementia is the rapid progress toward reliable biomarkers, especially those targeting alpha-synuclein, which is the core disease protein of Lewy body dementia, as well as Parkinson’s and what’s becoming clear, a co-pathology in Alzheimer’s. At ADDF, we’ve supported the development of a biomarker test from Amprion. And this test detects misfolded alpha-synuclein from just a few drops of cerebrospinal fluid, or CSF. So this will help physicians with early diagnosis of Parkinson’s, Lewy body dementia, as well as Alzheimer’s. And as I mentioned, this is because alpha-synuclein is gaining recognition as a key co-pathology in Alzheimer’s disease. So what’s becoming clear is that Lewy body dementia is finally becoming a biomarker-driven field, which is critical for better clinical trials and development of future treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
